CompletedPhase 2NCT01635283
Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
Studying Diffuse astrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jonsson Comprehensive Cancer Center
- Principal Investigator
- Robert PrinsJonsson Comprehensive Cancer Center
- Intervention
- tumor lysate-pulsed autologous dendritic cell vaccine(biological)
- Enrollment
- 5 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2016
Study locations (1)
- Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01635283 on ClinicalTrials.govOther trials for Diffuse astrocytoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06047379Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNeonc Technologies, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT04729959Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent GlioblastomaNational Cancer Institute (NCI)
- RECRUITINGPHASE4NCT03975829Pediatric Long-Term Follow-up and Rollover StudyNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGNANCT03739372Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade GliomaUniversity of California, San Francisco